免疫原性
佐剂
医学
病毒学
2019年冠状病毒病(COVID-19)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
信使核糖核酸
2019-20冠状病毒爆发
流感疫苗
接种疫苗
免疫学
抗原
生物
内科学
基因
疾病
爆发
传染病(医学专业)
生物化学
作者
Wen Shi Lee,Kevin J. Selva,Jennifer Audsley,Helen E. Kent,Arnold Reynaldi,Timothy E. Schlub,Deborah Cromer,David S. Khoury,Heidi Peck,Malet Aban,Mai N. Vu,Ming Z. M. Zheng,Amy W. Chung,Marios Koutsakos,Hyon‐Xhi Tan,Adam K. Wheatley,Jennifer A. Juno,Steven Rockman,Miles P. Davenport,Ian Barr
出处
期刊:JCI insight
[American Society for Clinical Investigation]
日期:2025-01-09
被引量:1
标识
DOI:10.1172/jci.insight.187075
摘要
BACKGROUND. The immunogenicity of current influenza vaccines need improvement. Inactivated influenza and COVID-19 mRNA vaccines can be co-administered but randomized controlled trial data is lacking on whether the two vaccines are more immunogenic if given in the same or opposite arms. Murine studies suggest mRNA vaccines can adjuvant influenza vaccines when co-formulated and delivered together.
科研通智能强力驱动
Strongly Powered by AbleSci AI